Biopharmaceutical company Soleno Therapeutics recently announced a major personnel appointment

According to documents submitted to the U.S. Securities and Exchange Commission (SEC) on February 25, the company has officially appointed Jennifer Fulk as Chief Financial Officer (CFO), with the appointment to take effect on March 2, 2026. This executive change marks an important step in Soleno Therapeutics' strategic planning. Jennifer Fulk has extensive experience in financial management and is expected to bring new momentum to the company's development. With the arrival of the new CFO, Soleno Therapeutics is expected to further strengthen its financial operations system, providing strong support for future business expansion.